CRISPR/Cas9: a breakthrough in generating mouse models for endocrinologists.
CRISPR/Cas9 is a recent development in genome editing which is becoming an indispensable element of the genetic toolbox in mice. It provides outstanding possibilities for targeted modification of the genome, and is often extremely efficient. There are currently two main limitations to in ovo genome editing in mice: the first is mosaicism, which is frequent in founder mice. The second is the difficulty to evaluate the advent of off-target mutations, which often imposes to wait for germline transmission to ensure genetic segregation between wanted and unwanted genetic mutations. However rapid progresses are made, suggesting that these difficulties can be overcome in the near future.
Institut de Génomique Fonctionnelle de LyonUniversité de Lyon, CNRS, INRA, École Normale Supérieure de Lyon, Lyon Cedex 07, France.
Suzy
S
Markossian
Institut de Génomique Fonctionnelle de LyonUniversité de Lyon, CNRS, INRA, École Normale Supérieure de Lyon, Lyon Cedex 07, France Frederic.Flamant@ens-lyon.fr.
Frédéric
F
Flamant
D000818:Animals; D064113:CRISPR-Cas Systems; D059766:DNA End-Joining Repair; D004195:Disease Models, Animal; D000072097:Endocrinologists; D004704:Endocrinology / Q000379:methods; D000072669:Gene Editing / Q000379:methods; D018390:Gene Targeting / Q000009:adverse effects / Q000379:methods; D051379:Mice; D008822:Mice, Transgenic; D009030:Mosaicism; D009865:Oocytes / Q000378:metabolism; D000094704:RNA, Guide, CRISPR-Cas Systems / Q000235:genetics; D059767:Recombinational DNA Repair
D000094704:RNA, Guide, CRISPR-Cas Systems
CRISPR; Cas9; genome editing; transgenic mice